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The aim of the study was to investigate which features predict favourable response to omeprazole therapy in
asthmatics with gastro-oesophageal reflux (GER).
The study population consisted of 52 outpatient asthmatics with GER who had completed an intervention where
they were randomized to receive omeprazole 40mg once a day or placebo for 8 weeks. After a 2-week washout
period the patients were crossed over. Asthma symptoms were found to be relieved  20% in 18 (35%) patients
who were thus regarded as responders. A logistic regression analysis was performed in order to identify which
features separate the responders from the non-responders.
More responders were found among the patients whose body mass index (BMI) was higher (P=0?02) or whose
distal esophageal reflux was more severe [total time (%) pH5 4 (P=0?01) or time (%) pH5 4 in upright position
(P=0?04)]. Adding other predictors to the total time (%) pH5 4, which was the most significant predictor for
response in multi-variate analysis, did not further increase the prediction for favourable outcome.
It is concluded that severe distal oesophageal reflux and obesity predict amelioration in asthma symptoms after
8-week omeprazole treatment in asthmatics with GER. Adding more than one predictor does not seem to further
increase prediction for favourable asthma response.
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Gastro-oesophageal reflux (GER) has been found to occur
in approximately half of asthmatic patients (1). Although
asthma is known to promote GER by increasing the
pressure gradient across the diaphragm (2), there is
evidence that GER can trigger asthma in some patients (3).
Several intervention studies with anti-reflux therapy have
been conducted in order to try to show some impact on
asthma outcome in asthmatics with GER. The results of
these studies are inconsistent. Some studies have been able
to show reduction in asthma symptoms after anti-reflux
therapy (4–6), whereas others have not (7–10), or only
nocturnal symptoms have ameliorated (11–14). Pulmonary
function or peak expiratory flow (PEF) values have
increased in a few studies (4,6,7,11) but in the majority of
the studies no change has been reported (5,8–10,12–14).
These conflicting results can be explained by different studyReveived 19 December 2000 and accepted in revised form
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lack of placebo control in some studies. Furthermore, it has
been noticed that not all asthmatics with GER respond to
the excessive anti-reflux therapy when pulmonary function
or asthma symptoms are concerned (14–16).
We have earlier found that distal oesophageal reflux is
more severe among the asthmatics who benefit from anti-
reflux therapy than in the asthmatics who do not benefit
(14). The aims of the present study are as follows: (1) to
investigate whether a systematic analysis could reveal
further parameters that would predict favourable response
to omeprazole 40 mg once a day therapy in asthmatics with
GER, and (2) to research whether adding more than one
predictor would further increase prediction for response.
Materials and methods
PATIENTS
The study population consisted of 52 asthmatics with GER
from the pulmonary outpatient clinic of Turku University
Central Hospital, Finland. Eighteen (35%) of the patients
were male and 34 (65%) were female. Their mean age was
50 (range, 21–75) years, PEF 455 (range, 250–700) lmin71# 2001 HARCOURT PUBLISHERS LTD
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of the patients were smokers and 49 (94%) used regular
inhaled steroids.
Diagnosis of asthma was made according to the guide-
lines defined by the American Thoracic Society (17).
Asthma was considered to be extrinsic if at least one
positive reaction was found in skin-prick tests with
common allergens. The presence of GER was ensured by
ambulatory oesophageal pH monitoring.
STUDY DESIGN
We previously performed an ambulatory oesophageal pH
monitoring on 107 outpatient asthmatics (14). Fifty-seven
patients found to have GER were randomized in a double-
blind fashion to receive either omeprazole 40mg (Astra,
Masala, Finland) once a day or a matched placebo for 8
weeks. After a 2-week washout period, patients were
crossed over to the other treatment for 8 weeks. Interven-
tion was preceded by a 1-week pretreatment phase during
which the baseline data were collected and a demographic
questionnaire was completed. Fifty-two patients completed
both treatment periods and thus formed the study
population in the present study.
Throughout the study the following symptoms were
recorded in a diary: cough, dyspnoea, wheezing, heartburn,
regurgitation, chest pain and night-time asthma symptoms.
Symptoms were recorded daily on a scale of 0 (no
symptoms) to 3 (severe symptoms). Afterwards, the weekly
pulmonary (cough, dyspnoea, wheezing) and gastric (heart-
burn, regurgitation, chest pain) symptom scores (both
0–63) and night-time asthma symptom score (0–21) were
calculated by summing the daily scores. In addition, the use
of inhaled b2-agonists and morning PEF values (Spira Peak
Flowmeter; Spira, Helsinki, Finland) were followed daily.
Spirometry (Flowscreen; Jaeger GmbH, Wu¨rzburg,
Germany) was performed on all patients before the first
treatment period and immediately after both treatment
periods. For a more detailed study design, we refer to our
previous article (14).
Patients were regarded as responders to the omeprazole
therapy if their pulmonary symptom score or PEF or FEV1
values improved on omeprazole from the baseline, and the
improvement was 20% or more compared with the placebo
(15,16). Based on symptom scores we found 18 (35%)
patients who were regarded as responders to the omepra-
zole therapy; no PEF or FEV1 responders were found (14).
A logistic regression analysis was performed in order to
identify which features predict response to the omeprazole
therapy. Variables included in the analysis are shown in
Table 1.
The study was approved by the Ethics Committee of
Turku University Central Hospital and every patient gave
written informed consent.
AMBULATORY pH MONITORING
All the patients had been asked to stop possible antacid,
H2-blocker, prokinetic or proton pump inhibitor medica-tion for at least 3 days before pH monitoring, and they were
also told to completely avoid these drugs during the
monitoring.
pH-recordings were made using semi-disposable pH
catheters (Synectics Medical, Stockholm, Sweden) with
15 cm spacing between the two monocrystant antimony
electrodes, which were calibrated before each procedure.
A pH probe was passed transnasally into the stomach,
then slowly withdrawn and a distal pH electrode was
positioned 5 cm above the lower oesophageal sphincter
(LES), as determined by the change in pH between the
stomach and the esophagus (18). An external reference
electrode was attached to the skin of the chest wall. pH was
stored at 4-sec intervals in a portable recorder (Digitrapper
Mk III; Synectics Medical). The parameters measured were
those described by Johnsson and DeMeester (19). After
ambulatory recording, the data was downloaded into an
IBM compatible computer using appropriate analysis
software (EsopHogram; Gastrosoft, Irving, Texas,
U.S.A.). The pH recording was considered to be abnormal
if the total time pH5 4 was over 4?5% or the DeMeester
score was over 14?7 (20). The DeMeester score, which takes
into account all six parameters measured in pH recording
(19), is calculated automatically by the software as
described elsewhere (21).
STATISTICAL ANALYSIS
The data are expressed as medians (25th–75th quartiles)
unless otherwise noted. Associations between possible
predictors of response to omeprazole therapy were analysed
by applying cross-tabulation and logistic regression analy-
sis. For each individual variable, univariate association was
tested first. Multi-variate stepwise logistic analysis was then
conducted for variables significant in univariate analysis.
Because of the outlying observations in numeric variables,
these were classified in four nearly equal sized quartiles
before logistic analysis. Test of trend in association was
then performed with these grouped measurements. Asso-
ciations were quantified with odds ratios and 95%
confidence intervals (22). The strength of association
between the severity of reflux and body mass index (BMI)
was quantified with Pearson’s correlation coecient. All
analyses were made using SAS statistical software (release
6?12; SAS Institute, Cary, North Carolina, U.S.A.).
P-values less than 0?05 were considered to be statistically
significant.
Results
Median (25th–75th quartiles), odds ratio, 95% confidence
interval and P-value for each variable are shown in Table 1.
More responders were found among the patients with
higher BMI (P=0?02), and in patients whose distal
oesophageal reflux was more severe: [total time (%)
pH54 (P=0?01) and time (%) pH54 in upright position
(P=0?04)]. Thus, these three variables were selected for
multi-variate stepwise logistic regression analysis, which
revealed that adding BMI (P=0?12) or time (%) pH54 in
TABLE 1. Comparison of patients who responded (n=18) and who did not respond (n=34) to the omeprazole therapy
Variable Responders Non-responders Odds ratio 95% CI P-value
Female/Male* 13 (72%)/5 (28%) 21 (62%)/13 (38%) 1?6 0?5–5?6 0?45
Smokers/Non-smokers* 3 (17%)/15 (83%) 5 (15%)/ 29 (85%) 1?2 0?2–5?5 0?85
Allergic/Non-allergic*{ 5 (33%)/10 (67%) 12 (44%)/15 (56%) 0?6 0?2–2?3 0?48
Age 49?0 (43?0–53?0) 49?0 (43?0–61?0) 0?9 0?5-1?5 0,69
BMI (kgm72) 29?7 (27?3–32?0) 27?1 (25?1–29?9) 2?0 1?1–3?6 0?02
FEV1 (% predicted) 76?8 (68?1–90?5) 85?7 (71?9–98?0) 0?7 0?4–1?3 0?28
FEV% 68?6 (61?4–81?7) 73?1 (63?9–80?6) 0?9 0?6–1?6 0?79
Pulmonary symptom score 14?5 (6?8–34?0) 10?0 (3?0–22?3) 1?4 0?8–2?3 0?25
Gastric symptom score 12?5 (5?3–20?0) 8?5 (2?0–20?3) 1?3 0?8–2?3 0?32
Nocturnal asthma symptom score 1?0 (0?0–10?3) 0?0 (0?0–4?5) 1?3 0?8–2?0 0?28
Use of rescue sympathomimetics 7?0 (1?0–22?0) 3?0 (0?0–21?0) 1?2 0?7–2?0 0?53
DeMeester Score 44?1 (21?8–70?5) 26?7 (17?3–50?0) 1?4 0?8–2?5 0?18
Number of reflux periods
Distally 65?0 (53?0–88?0) 65?0 (39?0–96?0) 1?1 0?7–1?9 0?65
Proximally 13?0 (10?0–32?0) 21?0 (7?0–30?0) 0?9 0?5–1?5 0?67
Longest reflux period (min)
Distally 40?0 (17?5–65?0) 27?0 (13?0–51?0) 1?3 0?7–2?1 0?38
Proximally 5?0 (1?0–9?0) 4?0 (2?0–7?0) 1?2 0?7–2?1 0?62
Time (%) pH5 4
Distally 10?9 (7?0–17?0) 8?0 (4?7–11?2) 2?0 1?1–3?7 0?01
Proximally 1?2 (0?3–2?9) 1?1 (0?6–2?0) 1?0 0?6–1?8 0?86
Time (%) pH5 4 (upright)
Distally 12?4 (8?0–18?9) 8?2 (5?7–14?8) 1?8 1?0–3?2 0?04
Proximally 0?7 (0?3–3?6) 1?7 (0?8–2?3) 0?7 0?4–1?2 0?14
Time (%) pH5 4 (supine)
Distally 7?7 (0?4–21?3) 4?1 (1?2–17?4) 1?0 0?6–1?7 1?00
Proximally 0?2 (0?0–1?4) 0?0 (0?0–0?6) 1?2 0?8–2?0 0?36
Data are presented as median (25th–75th quartiles), except *number of patients (percentage).
Univariate logistic regression model was utilized in calculation of odds ratios, 95% confidence intervals (95% CI) and
P-values. For these calculations each variable (except three first) was classified into four nearly equal sized quartiles and a
logistic model of trend was formulated.
*Odds ratio, 95% confidence interval and P-value quantify the difference between the two groups.
{Data available in only 42 patients.
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which was the most significant predictor for response, did
not further increase the prediction for favourable response.
When the whole study population of 52 patients was
concerned, a quarter of the patients had a higher value than
14?7% in total time (%) pH5 4. Forty-one per cent of the
responders and 18% of the non-responders belonged to this
highest quartile. A limit for the highest quartile in time (%)
pH54 in upright position was 15?1%. A higher value than
this was found in 35% of the responders and 18% of the
non-responders. Similarly, 41% of the responders and 15%
of the non-responders had a greater BMI than 30?3 kgm72,
which was a limit for the highest quartile (Fig. 1).
There was a weak, but only marginally significant,
correlation between severity of reflux [total time (%) pH
54] and BMI (r=0?28, P=0?05).
Nine patients were found whose pulmonary symptoms
improved on placebo from baseline and the improvement
was 20% or more compared with the omeprazole. All butone of these patients were among those who received
omeprazole during the first and placebo during the second
8-week treatment period. The 18 responders were distrib-
uted nearly equally between the two treatment groups: eight
of the responders were found among those who received
omeprazole during the first and placebo during the second
treatment period, and 10 among those who received drugs
in the reverse order.
Discussion
We have shown earlier that 35% of the asthmatics with
GER respond to 8 weeks of treatment with omeprazole at
40mg a day (14). In addition to severe distal oesophageal
reflux, we found that also an increase in BMI predicts a
favourable response to omeprazole therapy when asthmatic
symptoms are concerned. Since there is an association
between weight and GER (23), one could speculate that in
FIG. 1. By each variable, the whole 52-patient study group was divided into four 13-patient quartiles. The figure shows the
percentage of responders (n=18) (&) and non-responders (n=34) (&) in each of these quartiles. For this representation
only the variables found to be significant predictors for asthma response were chosen. Time (%) pH5 4 is the percentage of
the oesophageal pH registration time (total or while upright), during which the pH was 5 4.
390 T. KILJANDER ET AL.the present study obesity caused reflux to be more severe in
the responders and thus would be the ultimate reason for
response. However, we found total time (%) oesophageal
pH54 to be the most powerful single predictor for asthma
response, and adding BMI into the logistic model after total
time (%) oesophageal pH54 did not further increase the
prediction for response. Furthermore, there was only a
marginal correlation between the severity of reflux and
BMI (r=0?28). Thus, more severe distal oesophageal reflux
caused by obesity or by any other reason seems to be the
main factor in predicting asthma response to anti-reflux
therapy. Although pulmonary function was worse and
pulmonary and gastric symptoms were more severe among
the responders than in the non-responders, a statistically
significant difference could not be seen in these variables.
Similarly to our study, Harding et al. (16) found reflux to
be more severe in the asthmatics who responded to
omeprazole therapy. In contrast to our study, which
revealed distal oesophageal reflux to be a predictor for
response, they found the presence of regurgitation at least
once a week and proximal oesophageal reflux to predict a
response to omeprazole treatment. A retrospective study
found that 100% (n=4) of the patients with only
pathological proximal oesophageal reflux had a favourable
response to anti-reflux therapy (24). However, in that same
study it was also noticed that 82% of the patients (n=11)
with distal-only reflux gained benefit from anti-reflux
therapy. Gustafsson et al. (13) have also found a significant
positive correlation between asthma improvement after
anti-reflux therapy and the severity of GER.
After a 6-week omeprazole treatment, Meier et al. (15)
were able to show  20% improvement in FEV1-value in
four (27%) asthmatics with symptomatic GER and
oesophagitis. In that study all four responders and only55% of the non-responders had complete recovery of
oesophagitis. Although the non-responders seemed to have
more severe proximal and distal oesophageal reflux in their
study, no statistically significant difference was seen. In
contrast to our study, Meier et al. (15) found the non-
responders to be more obese than the responders. However,
a small number of responders in their study may have
influenced their result.
In other studies, several possible predictors have been
proposed. Ekstro¨m et al. (12) found that reflux-associated
respiratory symptoms identified patients whose asthma
outcome improved with ranitidine treatment. In some
studies, patients with intrinsic or dicult-to-control asthma
and GER have had a relief in asthmatic symptoms after
anti-reflux therapy (4,5,25). However, it must be kept in
mind that these studies were carried out entirely with
patients who had intrinsic or dicult-to-control asthma
and thus it cannot be concluded that patients with these
conditions did better than those without. A retrospective
study on surgical treatment of GER in asthmatics revealed
that in addition to severe reflux, the onset of typical reflux
symptoms before respiratory symptoms and the presence of
intrinsic asthma with predominance of nocturnal symptoms
predicted asthma improvement (26). Even in our previous
study, a relief in nocturnal asthma symptoms was found
after omeprazole treatment (14). However, the current
study revealed that the presence of intrinsic or nocturnal
asthma did not predict response to omeprazole treatment.
Unfortunately, the present study did not take into account
the possible relationship between reflux-associated respira-
tory symptoms and asthma response.
In addition to responders, we also found nine patients
whose pulmonary symptoms were relieved during the
placebo treatment. Interestingly, all but one of these
ASTHMA AND GASTRO-OESOPHAGEAL REFLUX 391patients were among those who received omeprazole during
the first and placebo during the second treatment period.
There are at least two explanations as to why so many
patients also responded to the placebo. Firstly, although no
statistically significant carryover effect after the washout
period was detected (14), there were two patients in whom
the amelioration in pulmonary symptoms continued after
the administration of the omeprazole was stopped. Sec-
ondly, a period effect may have been a factor. It is possible
that some patients who did not gain benefit from the
omeprazole during the first treatment period, improved
during the second treatment period due to the placebo
effect.
The period effect might have resulted in that some
patients have also been falsely interpreted as being
responders. However, for three reasons we believe that
there were only few, if any, such patients. Firstly, no
statistically significant period effect was detected (P=0?12)
when the whole study population was concerned. Secondly,
the responders were found equally among those who
received omeprazole during the first and placebo during
the second treatment period, and among those who received
drugs in the reverse order. Finally, in accordance with
previous studies (13,16,26) we found the severity of GER to
predict favourable response to anti-reflux therapy. This had
probably not been the case if the responders had not
actually been the responders.
We conclude that severe distal oesophageal reflux and
obesity predict amelioration in asthmatic symptoms after 8-
week omeprazole treatment in asthmatics with GER.
Adding more than one predictor does not seem to further
increase prediction for favourable response in these
patients.
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